Rosinsulin – 15 years on the market! As a tradition, the Medsintez Plant took part in the 5th (XXX) National Congress of Endocrinologists in Moscow

The 5th (XXX) National Congress of Endocrinologists «Innovative Technologies in Endocrinology» with international participation was held in Moscow from May 21 to 24, 2024, organized by the Russian Association of Endocrinologists and National Medical Research Center for Endocrinology, Federal State Budgetary Institution of the Russian Ministry of Health. Among the leading domestic and foreign pharmaceutical manufacturers, the Medsintez Plant presented its key products at the booth—genetically engineered and analogue human insulins Rosinsulin. Medical specialists who visited the exhibition expressed gratitude to the company for the affordability and high quality of its products.

The Medsintez Plant has been ensuring reliable drug safety for Russian diabetics for 15 years, providing the country with high-quality insulin drugs under the Rosinsulin trademark. The enterprise is one of the first industrial production facilities in Russia for finished dosage forms of genetically engineered human insulin that meet the requirements of GMP EC. For more than 20 years, the Medsintez Plant has been actively involved in the implementation of drug import substitution programs in the Russian Federation.

Today, the Plant is implementing the full-cycle production of the entire line of products of genetically engineered human insulin Rosinsulin and its analogue forms—Rosinsulin Aspart R and Rosinsulin Glargine from its own substances. Thus, the enterprise has passed the full cycle from the beginning of developing the molecule to the production and registration of finished insulin medicinal products. The project was implemented with the support of the Industrial Development Fund of the Russian Federation. Own production of insulin drugs allows to completely abandon purchases from foreign companies and offers a stable price for the finished drug in comparison with imported analogues.

High-tech Russian production implemented at the Plant ensures a world-class level of quality and safety of manufactured medicines. In 2007, the Medsintez Plant became the first pharmaceutical company in Russia being awarded the Russian Government Prize for Quality. According to the results of clinical studies, the insulin drugs Rosinsulin are completely bioequivalent and interchangeable with reference drugs. Rosinsulin is produced in the most convenient and familiar dosage forms for consumers – in vials, cartridges and injection pens.

Concern for consumers' health is a priority of the Medsintez Plant, so the enterprise has developed and patented the design of disposable and reusable injection pens that allow dosing the drug with high precision. Thanks to the ability to develop and produce its own devices for administering injectable drugs, the availability of its own research center and competencies in biotechnological processes, currently, the company is working on a number of projects to expand the range of insulin drugs.

In addition, in 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched a full-cycle production of hypoglycemic drugs for the treatment of type 2 diabetes mellitus—Liraglutide and Semaglutide. The production of domestic glucagon-like peptide 1 (GLP-1) receptor agonists will help fill the shortage of similar drugs arisen in the country due to the cessation of supplies from foreign manufacturers.

As part of the business program of the Congress, leading experts in the field of endocrinology discussed innovative methods and advanced strategies for diagnosing and treating endocrine diseases, considered more than thirty important topics, such as the epidemiology of endocrine diseases, insulin pump therapy and remote monitoring of children with type 1 diabetes, advanced technologies in reproductive medicine, radionuclide diagnostics and therapy of endocrine diseases, improvement of the system of higher medical education and many others.

Specialists from the Medsintez Plant attended the events of the Congress, including the most important meetings of the 4th Conference «Fundamental and Clinical Diabetology in the 21st Century: From Theory to Practice», as well as a forum on reproductive health. Since 2019, the Medsintez Plant has been producing the first Russian follicle-stimulating hormone drug Primapur for the treatment of human infertility, and has also been developing a full range of hormonal drugs used in the complex of assisted reproductive technologies.